SLU-PP-332 for fatigue and energy: reading the trials past the marketing

SLU-PP-332 gets talked about in fitness forums as an "exercise pill," and there are two solid mouse studies from a University of Florida lab behind that reputation. Short answer: for fatigue and energy specifically, SLU-PP-332 has real preclinical support at the level of mitochondria and muscle fiber type, but there is not a single human trial measuring whether it actually makes a tired person feel less tired.

I get asked about this one a lot, usually from people who are already deep into peptides and want to know if the exercise-mimetic story holds up or if it is just clever marketing wrapped around a chemical structure. Let me walk you through what the data supports and where it stops.

What the mouse data actually measured

The two core studies come out of Thomas Burris's lab, and they did not measure fatigue or energy directly. They measured the machinery that produces energy. In diet-induced obese mice, treated animals ended up 12 percent lighter than untreated controls after 28 days on an unchanged high-fat diet, with roughly ten times less fat accumulation, and their whole-body metabolism shifted toward burning fat as fuel. None of that came with a change in food intake, heart rate, or activity level, which matters because it rules out the usual explanation for weight loss in these models: the mice were not just eating less or moving more.

A separate paper looked inside the muscle itself and found increased mitochondrial respiration, a shift toward type 2A muscle fibers (the fatigue-resistant, oxidative kind), and upregulation of both PGC-1α and GLUT4, the two proteins that drive mitochondrial growth and glucose uptake respectively. Treated mice ran farther than controls, and when researchers blocked the ERR-alpha receptor, that endurance gain disappeared, which is about as clean a mechanistic link as you get in animal pharmacology. You can dig into the receptor biology and the fuller run of citations on the SLU-PP-332 encyclopedia entry if you want the full picture beyond the fatigue angle.

Why "exercise mimetic" is not the same claim as "energy booster"

Here is where I think the marketing gets ahead of the science. An exercise mimetic, in the strict sense used by these researchers, means a compound that turns on the same genetic program endurance training turns on, PGC-1α and mitochondrial biogenesis being the headline pathway. That is a real and interesting finding. It is not the same thing as a clinical claim that a fatigued person taking this compound will report more energy, sleep better, or push through their afternoon slump. Nobody has run that trial. The animal studies were built to test metabolic and exercise-performance endpoints in mice, and mouse endurance on a treadmill does not automatically translate to a person feeling less wiped out at 3pm.

I try to stay evidence-based with peptides, and this is a case where I want to be excited about the mechanism while staying clear that the mechanism and the human outcome are two different questions. Compare that to something like 5-Amino-1MQ, which also gets pitched for energy and where the evidence base has its own gaps worth reading before you commit to either one.

The distinction from stimulant-based energy is genuine, though, and worth sitting with. Caffeine, yohimbine, and most thermogenics work by pushing catecholamines through the sympathetic nervous system, which is why they come with a jittery edge and a crash later. In the rodent studies, SLU-PP-332 produced none of that: no heart rate change, no appetite suppression, no sympathetic activation. If the human effect holds anything like the animal profile, the source of any energy gain would be cellular, more functioning mitochondria doing their job, rather than borrowed from your adrenal glands. That is a real difference in mechanism even if we cannot yet say it is a real difference in how a person feels.

The related molecule SLU-PP-915 has a small amount of additional animal support too. A 2026 paper found it enhanced aerobic exercise capacity in mice through the same pan-ERR pathway, and separate anti-aging work on ERR agonism found it reversed kidney dysfunction and inflammation in aging mice over an eight-week course. Neither of those is a fatigue trial either, but they add weight to the idea that this receptor family does something real metabolically across multiple tissue types, not just in one lab's muscle assay. There is also a 2026 mass spectrometry paper that characterized how the body metabolizes SLU-PP-332, which matters less for the energy question and more for the fact that anti-doping scientists are already building test methods for it. That is usually a sign researchers think a compound has real performance-enhancing potential, not that it is a dead end.

What this means if you are using it for fatigue right now

If you are someone dealing with real fatigue, whether that is training burnout, metabolic sluggishness, or just running on empty most days, I understand the appeal of a compound with this clean a mechanistic story. The biology is worth watching closely, and the human evidence is not there yet. I would not build a fatigue protocol around SLU-PP-332 alone right now, and I would not tell someone dealing with genuine chronic fatigue to skip working with a doctor to rule out thyroid, iron, sleep apnea, or the dozen other common causes just because a mouse study looked promising.

There is no established human dosing protocol for this one, which is different from most of the peptides I write about where a real-world community protocol has emerged alongside the animal data. That has not happened yet with SLU-PP-332. Reconstitution itself is also different from the peptides you are used to: it is a hydrophobic small molecule that will not dissolve in bacteriostatic water, it needs DMSO, and DMSO is a penetration enhancer that carries whatever is dissolved in it across skin, so purity of your source material matters more here than usual.

Now the part my lawyer makes me say, and he is right: the doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

If you are looking into vendors for this or any other compound in this family, third-party testing and documented sourcing matter a lot, arguably more here given the DMSO handling and the newer, thinner literature. I'd rather see you cautious with something this early-stage than convinced by a forum post.

SLU-PP-332 has better rodent data than most exercise-mimetic candidates I cover, and it still needs a human trial before anyone can responsibly call it an energy fix. I will keep watching this one and update as the picture changes.